MedicaidCoverageMedium impact
Genetic Testing for Diagnosis of Inherited Conditions - MEDICAID - OKLAHOMA (New)
Humana·OK · Genetics, Hematology, Neurology +3 more·Medicaid
Effective date
Sep 2, 2026
We identified it
Sep 2, 2026
Summary
Humana Oklahoma Medicaid has released a new genetic testing coverage policy (effective 09/02/2026) that establishes medical necessity criteria and coding requirements for genetic testing to diagnose inherited conditions including adrenoleukodystrophy, corneal dystrophy, hemophilia B, myotonic dystrophy, and other genetic disorders. Billing teams must ensure pre- and post-test genetic counseling documentation and verify specific clinical criteria are met before submitting claims for covered genetic tests.
Action Required
By September 2, 2026: Billing and clinical teams must implement the following: (1) Update billing system to require documentation of pre- and post-test genetic counseling for all genetic testing claims submitted under this policy; (2) Create clinical decision support tools or checklists in the EMR/billing software to verify medical necessity criteria are met before claim submission—specifically: for adrenoleukodystrophy (ABCD1 gene), corneal dystrophy (TGFBI gene 81333), hemophilia B (F9 gene 81238), myotonic dystrophy (DMPK/CNBP genes), and molecular pathology testing (81479); (3) Train providers and billing staff on the specific eligibility criteria for each condition (e.g., carrier screening, positive newborn screen, equivocal diagnosis, symptomatic presentation with imaging/lab findings); (4) Update claim submission forms and prior authorization request templates to include required clinical documentation; (5) Implement claims denial prevention by rejecting incomplete submissions lacking evidence of genetic counseling or unmet clinical criteria. Failure to include required documentation or meet specified criteria will result in claim denials under this new Humana Oklahoma Medicaid policy.